. Further analysis of this vector is needed to advance development into clinical trials. In this study we have defined the precise nature of the multiple IE gene mutations in the d106 viral gene and have used this information to construct a new transfer plasmid for gene transfer into d106. We tested the effect of an additional mutation in the U L 41 gene on d106 immunogenicity and found that it did not improve the efficacy of the d106 vector, in contrast with results from other studies with U L 41 gene mutants. The safety profile of d106 was improved by generating a new vector strain, d106S, with increased sensitivity to acyclovir. Finally, we have constructed a d106S recombinant vector that expresses the HIV clade C envelope protein. The d106S-HIVenvC recombinant has retained the sensitivity to acyclovir, indicating that this phenotype is a stable property of the d106S vector.
ICP22 genes and between the ICP4 and ICP47 genes [13] ; Fig. 1C ).
97
These deletions remove an Oct-1 site, effectively making the ICP22 98 and ICP47 genes into early genes whose expression is dependent on 99 ICP4 provided by the complementing cell line [13] . Our sequencing 146,695 was replaced by a 16-bp sequence, GCTCTAGATTAATTAA, used as a linker in the construction of the TGT mutation (Fig. 2C ).
104
The [17] , and this approach has been used to introduce expression cas-125 settes into the HSV genome to generate vaccine vectors [12, 14] .
126
We had used the pPs27pd1 plasmid (Fig. 3) from d106 DNA using primer pairs A and B, respectively (Table 1) .
137
The PCR fragments were gel purified and ligated with TA plasmid 
Effect of vhs inactivation on immunogenicity of d106 vectors

152
Previous studies have reported that inactivation of the vhs func-153 tion can increase immunogenicity of HSV strains in some situations 154 [18] [19] [20] , although not all situations [21] . We wanted to determine showed an IC 50 of 13 M (Fig. 6) . For an optimal safety profile, an 6 PFU of d106-gag or RJ-1-gag virus, followed by two booster inoculations at week 3 and week 6. Splenocytes were collected at week 4 and week 7 for ELISPOT as described in Fig. 4 . Serum samples were collected at week 0, week 3, and week 6 prior to booster inoculation, and week 9 after booster. were plaque-purified, and expression of env protein was assessed 242 (Fig. 7A) . One of the recombinant viruses was chosen as the proto-243 type strain and was shown to express env protein for at least 24 h 244 (Fig. 7B) . Furthermore, the recombinant virus was highly sensitive which does not express any IE genes [13] .
335
In summary, we have modified the HSV-1-d106 vector system 336 by generating the d106S virus strain with increased acyclovir sensi-337 tivity. Furthermore, the d106S virus strain shows the properties of 338 limited cytopathic effect and prolonged expression of transgenes.
339
We are now constructing and characterizing a set of d106S vectors 340 expressing HIV proteins for future clinical trials.
